New Member appointed to the Board of Directors of Neuralstem
December 20 2017 - 7:30AM
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today
announced that Xi Chen, Ph.D., has been appointed to its
Board of Directors, effective immediately. Dr. Chen was appointed
by Tianjin to replace Zhang Zhuo as the director appointee of the
Series A Convertible Preferred Stock.
“It is our pleasure to welcome Dr. Chen to the Board of
Directors,” said Rich Daly, Chairman and CEO. “Dr. Chen comes to us
with years of therapeutic development and administrative expertise,
and the contributions and guidance that he has to offer will be
highly valuable to the future of the Company.”
Dr. Chen has served as the Assistant General Manager of
Manufacture, Equipment, and Administration at Tianjin Kinnovata
Pharmaceutical since 2014. He also served as the Deputy Director of
the Marketing Department at Tianjin Pharmaceutical Holdings since
2012. Previously, Dr. Chen was the Executive Vice General Manager
of Tianjin Lights Medical Device Co., and a Research Associate, Lab
Manager at the University of Ottawa, and Anesthesiologist at
Tianjin Union Hospital.
Dr. Chen. holds a PhD in Enterprises Management, a Master’s
Degree in Molecular Biology from University of Ottawa, and a
Clinical Bachelor’s Degree from Tianjin Medical University.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company
developing novel treatments for nervous system diseases of high
unmet medical need. NSI-189 is a small molecule in clinical
development for major depressive disorder (MDD) and in preclinical
development for Angelman syndrome, irradiation-induced cognitive
impairment, Type 1 and Type 2 diabetes, and stroke. NSI-566
is a stem cell therapy being tested for treatment of paralysis in
stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral
Sclerosis (ALS). Neuralstem’s diversified portfolio of
product candidates is based on its proprietary neural stem cell
technology.
Cautionary Statement Regarding Forward Looking Information
This news release contains “forward-looking statements” made
pursuant to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
relate to future, not past, events and may often be identified by
words such as “expect,” “anticipate,” “intend,” “plan,” “believe,”
“seek” or “will.” Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Specific
risks and uncertainties that could cause our actual results to
differ materially from those expressed in our forward-looking
statements include risks inherent in the development and
commercialization of potential products, uncertainty of clinical
trial results or regulatory approvals or clearances, need for
future capital, dependence upon collaborators and maintenance of
our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Neuralstem’s periodic reports, including the
Annual Report on Form 10-K for the year ended December 31, 2016,
and Form 10-Q for the three and nine months ended September 30,
2017, filed with the Securities and Exchange Commission (SEC), and
in other reports filed with the SEC. We do not assume any
obligation to update any forward-looking statements.
Contact:Kimberly MinarovichArgot Partners (Investor
Relations)212-600-1902kimberly@argotpartners.com
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2024 to May 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From May 2023 to May 2024